

Stefan Verlohren

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8860048/stefan-verlohren-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83
papers

4,076
citations

31
h-index

63
g-index

101
ext. papers

4,830
ext. citations

5
avg, IF

5.1
L-index

#	Paper	IF	Citations
83	sFlt-1/PLGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation.. <i>PLoS ONE</i> , 2022 , 17, e0263443	3.7	1
82	Correlation between placental weight and angiogenic markers sFlt-1 and PLGF in women with preeclampsia and fetal growth restriction.. <i>Pregnancy Hypertension</i> , 2022 , 28, 149-155	2.6	0
81	Clinical interpretation and implementation of the sFlt-1/PLGF ratio in the prediction, diagnosis and management of preeclampsia.. <i>Pregnancy Hypertension</i> , 2021 , 27, 42-50	2.6	6
80	Differential diagnosis of syndromic craniosynostosis: a case series. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 1	2.5	0
79	Short Term Prediction of Preeclampsia. <i>Maternal-Fetal Medicine</i> , 2021 , 3, 107-115	0.6	2
78	Preeclampsia: Universal Screening or Universal Prevention for Low and Middle-Income Settings?. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021 , 43, 334-338	1.1	
77	A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics). <i>International Journal of Gynecology and Obstetrics</i> , 2021 , 154 Suppl 1, 3-31	4	6
76	Prognostic significance of prenatal ultrasound in fetal arthrogryposis multiplex congenita. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 943-953	2.5	1
75	Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PLGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study. <i>Hypertension</i> , 2021 , 77, 461-471	8.5	22
74	Gestational Age-Specific Reference Ranges for the sFlt-1/PLGF Immunoassay Ratio in Twin Pregnancies. <i>Fetal Diagnosis and Therapy</i> , 2021 , 48, 288-296	2.4	2
73	Maternale Erkrankungen in der Schwangerschaft 2021 , 337-609		
72	Relevance of maternal sodium level for preeclampsia-associated adverse pregnancy outcomes. <i>Pregnancy Hypertension</i> , 2021 , 25, 110-115	2.6	1
71	Cost-utility of a first-trimester screening strategy versus the standard of care for nulliparous women to prevent pre-term pre-eclampsia in Belgium. <i>Pregnancy Hypertension</i> , 2021 , 25, 219-224	2.6	2
70	The growing body of evidence for the implementation of the soluble fms-like tyrosine kinase 1/placental growth factor ratio into clinical routine. <i>American Journal of Obstetrics and Gynecology</i> , 2021 ,	6.4	
69	Role of placenta in development of pre-eclampsia: revisited. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020 , 56, 803-808	5.8	1
68	Statins Reverse Postpartum Cardiovascular Dysfunction in a Rat Model of Preeclampsia. <i>Hypertension</i> , 2020 , 75, 202-210	8.5	16
67	The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2020 ,	6.4	12

66	From first-trimester screening to risk stratification of evolving pre-eclampsia in second and third trimesters of pregnancy: comprehensive approach. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020 , 55, 5-12	5.8	13
65	Kagami-Ogata syndrome: an important differential diagnosis to Beckwith-Wiedemann syndrome. <i>Journal of Clinical Ultrasound</i> , 2020 , 48, 240-243	1	5
64	Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019 , 53, 367-375	5.8	54
63	Präeklampsierisiko – was ist zur Überwachung in der Gravidität sinnvoll?. <i>Der Gynakologe</i> , 2019 , 52, 845-850	0.1	
62	Author's reply re: Pre-eclampsia is primarily a placental disorder: FOR: Pre-eclampsia is primarily a placental disorder. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018 , 125, 513-514	3.7	
61	Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/PlGF Ratio in Singleton Pregnancies. <i>Fetal Diagnosis and Therapy</i> , 2018 , 43, 81-89	2.4	57
60	Re: Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study. E. Sabri, P. Lequerica-Fernández, P. Lafuente-Ganuza, E. Eguia-Begeles, A. I. Escudero, E. Martínez-Morillo, C. Barcel and F. V. Vare. <i>Ultrasound Obstet Gynecol</i> 2018; 51: 1197-1200	5.8	
59	Kongressnachlese: Präeklampsie – Screening/Prädiktion/Prävention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018 , 78, 1197-1200	2	
58	Soluble B7-H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsia. <i>American Journal of Reproductive Immunology</i> , 2018 , 80, e12988	3.8	7
57	Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay Kryptor®. <i>Pregnancy Hypertension</i> , 2017 , 8, 31-36	2.6	12
56	Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies. <i>Hypertension in Pregnancy</i> , 2017 , 36, 151-160	2	27
55	Increased placental sFlt-1 but unchanged PlGF expression in late-onset preeclampsia. <i>Hypertension in Pregnancy</i> , 2017 , 36, 175-185	2	12
54	Angiogenic Markers and Cardiovascular Indices in the Prediction of Hypertensive Disorders of Pregnancy. <i>Hypertension</i> , 2017 , 69, 1192-1197	8.5	42
53	Re: Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017 , 49, 665-666	5.8	1
52	. <i>Journal Für Gynakologische Endokrinologie</i> , 2017 , 27, 153-158	0.1	
51	Pre-eclampsia is primarily a placental disorder: FOR: Pre-eclampsia is primarily a placental disorder. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017 , 124, 1762	3.7	5
50	Re: Rational and irrational ratios. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017 , 49, 157-158	5.8	3
49	Präeklampsie. <i>Der Gynakologe</i> , 2017 , 50, 213-221	0.1	1

48	Präeklampsie. <i>Journal für Gynäkologische Endokrinologie/Schweiz</i> , 2017 , 20, 157-161		0
47	Maternale Erkrankungen in der Schwangerschaft 2016 , 347-618		
46	Natural Killer Cell Reduction and Uteroplacental Vasculopathy. <i>Hypertension</i> , 2016 , 68, 964-73	8.5	12
45	Predictive Value of the sFlt-1:PLGF Ratio in Women with Suspected Preeclampsia. <i>New England Journal of Medicine</i> , 2016 , 374, 13-22	59.2	761
44	Predictive Value of the sFlt-1. <i>Obstetrical and Gynecological Survey</i> , 2016 , 71, 273-274	2.4	4
43	Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia. <i>Obstetrics and Gynecology</i> , 2016 , 128, 261-269	4.9	46
42	A comparison of the diagnostic utility of the sFlt-1/PLGF ratio versus PLGF alone for the detection of preeclampsia/HELLP syndrome. <i>Hypertension in Pregnancy</i> , 2016 , 35, 295-305	2	32
41	The sFlt-1:PLGF Ratio in Women with Suspected Preeclampsia. <i>New England Journal of Medicine</i> , 2016 , 374, 1785-6	59.2	20
40	Maternal serum sFlt-1/PLGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015 , 45, 286-93	5.8	41
39	Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy. <i>Fetal Diagnosis and Therapy</i> , 2015 , 37, 81-92	2.4	47
38	Update Ersttrimesterscreening [was ist neu in 2015?]. <i>Frauenheilkunde Update</i> , 2015 , 9, 243-255	0.1	
37	Implementation of the sFlt-1/PLGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015 , 45, 241-6	5.8	148
36	Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. <i>Prenatal Diagnosis</i> , 2015 , 35, 386-93	3.2	25
35	Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. <i>Hypertension in Pregnancy</i> , 2014 , 33, 427-39	2	28
34	Uterine artery Doppler, birth weight and timing of onset of pre-eclampsia: providing insights into the dual etiology of late-onset pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014 , 44, 293-8	5.8	73
33	Re: Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk for pre-eclampsia. A. Khalil, N. Maiz, R. Garcia-Mandujano, M. Elkhoul and K. H. Nicolaides. <i>Ultrasound Obstet Gynecol</i> 2014; 44: 402-410. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014 , 44, 386	5.8	
32	Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. <i>Obstetrics and Gynecology</i> , 2014 , 124, 265-273	4.9	63
31	New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. <i>Hypertension</i> , 2014 , 63, 346-52	8.5	199

30	The importance of repeated measurements of the sFlt-1/PLGF ratio for the prediction of preeclampsia and intrauterine growth restriction. <i>Journal of Perinatal Medicine</i> , 2014 , 42, 61-8	2.7	48
29	Biomarker in der Pränataldiagnostik. <i>Der Gynakologe</i> , 2013 , 46, 397-402	0.1	
28	SLC41A1 is the only magnesium responsive gene significantly overexpressed in placentas of preeclamptic women. <i>Hypertension in Pregnancy</i> , 2013 , 32, 378-89	2	20
27	Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. <i>Hypertension in Pregnancy</i> , 2013 , 32, 189-201	2	106
26	Antiangiogenic factors and maternal hemodynamics during intensive hemodialysis in pregnancy. <i>Hemodialysis International</i> , 2013 , 17, 639-43	1.7	16
25	Automated measurement of sFlt1, PLGF and sFlt1/PLGF ratio in differential diagnosis of hypertensive pregnancy disorders. <i>Hypertension in Pregnancy</i> , 2013 , 32, 459-73	2	24
24	Re: uterine artery Doppler and sFlt-1/PLGF ratio: usefulness in diagnosis of pre-eclampsia. P. I. Gñez-Arriaga, I. Herraiz, E. A. Lpez-Jimnez, E. Gñez-Montes, B. Denk and A. Galindo. <i>Ultrasound Obstet Gynecol</i> 2013; 41: 530-537. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013 , 41, 489-90	5.8	1
23	Pränklampsie und Diabetes mellitus in der Schwangerschaft. <i>Monatsschrift Fur Kinderheilkunde</i> , 2012 , 160, 1204-1210	0.2	
22	The sFlt-1/PLGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. <i>American Journal of Obstetrics and Gynecology</i> , 2012 , 206, 58.e1-8	6.4	251
21	Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. <i>Clinical Science</i> , 2012 , 122, 43-52	6.5	109
20	Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. <i>Circulation</i> , 2012 , 126, 2990-9	16.7	48
19	Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. <i>Circulation</i> , 2012 , 125, 911-9	16.7	411
18	Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. <i>Hypertension</i> , 2012 , 60, 451-8	8.5	69
17	L13. The routine measurement of the sFlt1/PLGF ratio allows differential diagnosis of hypertensive pregnancy disorders and has prognostic potential in preeclamptic patients. <i>Pregnancy Hypertension</i> , 2011 , 1, 245-6	2.6	6
16	Inhibition of trophoblast-induced spiral artery remodeling reduces placental perfusion in rat pregnancy. <i>Hypertension</i> , 2010 , 56, 304-10	8.5	60
15	Effects of circulating and local uteroplacental angiotensin II in rat pregnancy. <i>Hypertension</i> , 2010 , 56, 311-8	8.5	54
14	Frñgeburtlichkeit. <i>Frauenheilkunde Up2date</i> , 2010 , 4, 235-247	0.1	1
13	Changes in endovascular trophoblast invasion and spiral artery remodelling at term in a transgenic preeclamptic rat model. <i>Placenta</i> , 2010 , 31, 320-6	3.4	33

12	An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2010 , 202, 161.e1-161.e11	6.4	277
11	Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. <i>Hypertension</i> , 2009 , 53, 393-8	8.5	78
10	Immunology in hypertension, preeclampsia, and target-organ damage. <i>Hypertension</i> , 2009 , 54, 439-43	8.5	47
9	Präeklampsie und hypertensive Schwangerschaftserkrankungen. <i>Frauenheilkunde Up2date</i> , 2009 , 3, 461-472	8.5	2
8	Hypoxia induces dilated cardiomyopathy in the chick embryo: mechanism, intervention, and long-term consequences. <i>PLoS ONE</i> , 2009 , 4, e5155	3.7	95
7	Endovascular trophoblast invasion, spiral artery remodelling and uteroplacental haemodynamics in a transgenic rat model of pre-eclampsia. <i>Placenta</i> , 2008 , 29, 614-23	3.4	51
6	Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. <i>Hypertension</i> , 2008 , 51, 554-9	8.5	26
5	Uterine vascular function in a transgenic preeclampsia rat model. <i>Hypertension</i> , 2008 , 51, 547-53	8.5	69
4	Präeklampsie – Eine Multisystemerkrankung in der Schwangerschaft. <i>Dialyse Aktuell</i> , 2008 , 12, 300-304	0.1	
3	Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension. <i>PLoS ONE</i> , 2008 , 3, e3742	3.7	74
2	Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. <i>Circulation Research</i> , 2005 , 97, 1253-61	15.7	35
1	Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. <i>Hypertension</i> , 2004 , 44, 271-6	8.5	226